According to the average brokerage recommendation (ABR), one should invest in Novo Nordisk (NVO). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
AbbVie (ABBV) offers to buy Cerevel Therapeutics (CERE) for $8.7 billion. The acquisition will strengthen AbbVie's neuroscience pipeline.
J&J (JNJ) expects operational sales growth in the range of 5-6% in 2024, driven by both its Innovative Medicine and MedTech divisions.